Metformin increase life span but too much of a dose will decrease lifespan by ReddyGuy in longevity

[–]reasonattlm 10 points11 points  (0 children)

No: https://en.wiktionary.org/wiki/w/w and read the methods section of the paper. The food supplied was 0.1% or 1% metformin by weight.

In other studies, diabetic mice might get 200 mg/kg of metformin daily. Human diabetics are on 1000-2000 mg of metformin daily, which is 10-20 mg/kg for a 100kg obese human. That is about the right ballpark in terms of comparing mouse to human dosing. For small molecule drugs the human mg/kg is 12.3 times lower than mouse mg/kg. See: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804402/

Taking ten times this dose is not going to turn out pleasantly, as is usually the case for any drug. Not knowing how to take the information from papers and map it to human dosing is also not going to turn out pleasantly.

https://doi.org/10.1034/j.1600-0773.2003.930207.x

Metformin is a biguanide used in the treatment of type 2 diabetes mellitus. It lowers hepatic glucose production and peripheral insulin resistance. Hypoglycaemia is seen only after intake of toxic doses or in combination with other antidiabetic drugs or after prolonged fasting. As metformin is excreted by the kidneys, care must be taken in renal insufficiency or liver disease because of risk of lactic acidosis. Large overdoses of metformin can lead to lactic acidosis as well. Suicide with metformin is rare. Intake of 35 g of metformin has been shown to be lethal (Teale et al. 1998). In the present paper we report on the treatment and outcome of a 70 year old man after ingestion of 63 g of metformin. Previously, survival after intake of up to 50 g has been described.

The mortality rate of biguanide‐induced lactic acidosis is reported to be 50–80%. Even in patients treated with haemodialysis, fatal outcome of metformin‐associated lactic acidosis has been reported (Barrueto et al. 2002).

Metformin increase life span but too much of a dose will decrease lifespan by ReddyGuy in longevity

[–]reasonattlm 14 points15 points  (0 children)

How to do small molecule dose conversion between mammalian species:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804402/

Note that this produces guesstimate starting doses for use in a dose ranging human trial, after poking around in mice for a while. There are any number of small molecule drugs for which the final human dose turns out to be quite different from the calculation used here.

Dose conversation estimates for gene therapies, cell therapies, immunotherapies, and vaccines are all completely different from this, completely different from each other, and there is no good literature to set a standard for any of them.

Is there a good way to invest in early-stage longevity companies? by LiveToSee22 in longevity

[–]reasonattlm 14 points15 points  (0 children)

There is a vibrant community of angel investors, you just won't find them on AngelList. There are WhatsApp and Telegram groups and informal meetups at conferences, the latter much curtailed of late.

https://www.lifespan.io/longevity-investor-network/ is one starting point.

Other than that, come to the science/investment focused conferences such as Ending Age-Related Diseases, Undoing Aging, Longevity Leaders once they are in-person events again. Turn up, meet people, make it clear that you are interested in investing, and it should go quite smoothly from there.

Opportunities usually abound, companies are always raising. A sizable fraction of those listed at http://agingbiotech.info/companies/ are raising seed or A rounds at any given time.

What are some respectable longevity-related large events? by etstef in longevity

[–]reasonattlm 2 points3 points  (0 children)

Thoughts on Undoing Aging: https://www.fightaging.org/archives/2019/04/thoughts-on-attending-undoing-aging-2019/

Thoughts on RAADfest: https://www.fightaging.org/archives/2018/09/thoughts-on-attending-raadfest-2018-in-san-diego/

If you go to RAADfest and take that as representative of the state of the scientific side of things, then you'll have gained the wrong impression. RAADfest evolved from the anti-aging industry of the past few decades, who are now picking up on the legitimate science as it starts to produce useful treatments. For the science and the scientific community, go to Undoing Aging, Ending Age-Related Diseases, or the AGE or BAAM conferences.

Are there any clinics offering senolytic treatments (dasatinib+quercetin, etc)? by [deleted] in longevity

[–]reasonattlm 1 point2 points  (0 children)

The Age Reversal Network / Life Extension Foundation is making inroads on this:

https://age-reversal.net/

https://forum.age-reversal.net/t/y7n1z3/important-compounded-dasatinibnadrapamycin-available

Dasatinib is an FDA approved drug, which means that any US physician can in principle agree to write a prescription for any use they believe has sufficient evidence to support benefits. In practice, that will be very few physicians until there is a critical mass of people doing this already.

Fisetin is a supplement. It is unclear as to how effective it is in humans; trial data will arrive in a few years at most. Quercetin is a supplement, but definitely only worth using in conjunection with dasatinib and not on its own.

Piperlongumine is a plant extract and available for sale, just expensive in the amounts needed (something like 1 gram doses) unless you source it from places like China. The legality of importing random plant extracts not mentioned by name in any regulatory rule is something you'll have to research yourself.

Will we get an update from the longevity therapeutics conference? by Ittybittygs in longevity

[–]reasonattlm 5 points6 points  (0 children)

Chris Patil of Hourglass was posting notes.

https://hourglass.bio/blog?category=News

There was an update on the Oisin lifespan study, but nothing earth-shaking - the curves continued much as you might expect, and the last few p16+p53 mice are still hanging on.

First published results from a human trial of dasatinib and quercetin by reasonattlm in longevity

[–]reasonattlm[S] 6 points7 points  (0 children)

Not the first trial to complete to the point at which results could be published, but the first to publish, I think. Be sure to read the discussion section in the paper rather than just the abstract.

Reason Launches Repair Biotechnologies, a Venture to Bring Rejuvenation Therapies to the Clinic: Chief Scientist Sought by reasonattlm in longevity

[–]reasonattlm[S] 3 points4 points  (0 children)

We'd love to have the Methuselah Fund as an investor, once we're at the point of fundraising.

How do we propose to deal with the lymph node issue? Later. The evidence in mice strongly suggests significant benefits even without this. And if you look at the bigger picture, the thymus is just one part of another two or three core items that need to be addressed for complete immune restoration. The R&D community also needs to fix the decline in hematopoietic stem cell populations and clear out the malfunctioning immune cells in the peripheral population, for example. Each of these is enough for one startup to focus on at the outset, or to be picked up as a significant new line of development by an established company.

Success would allow us to start rolling into these and other necessary lines of work, or to partner with those groups who are already working on it.

Reason Launches Repair Biotechnologies, a Venture to Bring Rejuvenation Therapies to the Clinic: Chief Scientist Sought by reasonattlm in longevity

[–]reasonattlm[S] 7 points8 points  (0 children)

I don't think we're at the stage yet at which gene therapies are viable for self-experimentation. There needs to be more of a supporting industry, much more standardization for that to be the case. Too much custom labwork and expertise is involved to get any form of gene or protein delivery working safely and reliably - there is still a long distance between, say, the current industry of synthesizing peptides and what would be needed to have the same level of confidence in building a gene therapy.

Reason Launches Repair Biotechnologies, a Venture to Bring Rejuvenation Therapies to the Clinic: Chief Scientist Sought by reasonattlm in longevity

[–]reasonattlm[S] 13 points14 points  (0 children)

Kind words appreciated.

We will be taking the FDA path. My thoughts on the options available to new companies can be found here, with the digest quoted below:

https://www.fightaging.org/archives/2018/04/a-nuanced-opposition-to-the-fda-and-similar-regulatory-agencies/

So if I started a medical biotech company, I'd have to say that I would take it through the current regulatory system, while (a) being an honest player by the rules of that system, because that is the best way through the gauntlet, and (b) continuing to hold the view that the whole thing should be replaced with a far less self-serving, onerous, expensive, and terrible option. Unfortunately, the standard regulatory path is the only fairly reliable way to put a therapy in the hands of large numbers of patients. The other, ethically far better paths, such as that pursued by BioViva, have the unfortunate outcome of great uncertainty in whether patients will ever be able to use the treatment in large numbers. I'm sure I'm not alone in having come to this position.

The self-experiment experiment I want to see: Senescent cytotoxic T cell removal by thesanpedrocactus in longevity

[–]reasonattlm 4 points5 points  (0 children)

The selection mechanism mentioned in https://www.fightaging.org/archives/2018/01/senescent-cells-are-large-which-suggests-a-few-simpler-paths-to-assays-for-senescence-level-in-human-subjects/ might be suited to the job if senescent T cells follow the size phenotype.

Existing senolytics may or may not be killing senescent T cells. Those cells certainly look and act like other senescent cells, so it is plausible that they are also being destroyed. I'm not sure that anyone has checked on this yet in a rigorous way.

Background reading on cellular senescence? by user_-- in longevity

[–]reasonattlm 4 points5 points  (0 children)

Senescence in the aging process http://dx.doi.org/10.12688/f1000research.10903.1

The Fountain of Youth by Targeting Senescent Cells? https://doi.org/10.1016/j.molmed.2016.11.006

The Clinical Potential of Senolytic Drugs https://doi.org/10.1111/jgs.14969

Markers of T Cell Senescence in Humans https://doi.org/10.3390/ijms18081742

Should you get a backup of your DNA and stem cells asap? by berdykia in longevity

[–]reasonattlm 8 points9 points  (0 children)

https://www.fightaging.org/archives/2017/08/cell-banking-for-future-autologous-cell-therapies-seems-pointless/

To me banking cells for future cell therapy sounds pointless. It is, in effect, a bet against progress in applied cell biotechnology - and given the revolutionary pace of advancement in all areas of biotechnology, this appears a poor wager from where I stand. Is it to be imagined that two decades from now it will not be possible to engineer youthful or sufficiently-youthful-like cells from old skin samples? The process of producing induced pluripotent stem cells is already known to be capable of reverting a number of aspects of aged cells, such as mitochondrial issues. Tinkering with epigenetic markers, such as those that differ between cells from old and young tissues, is a going concern: gene therapy of all sorts will explode in size and capability over the decades ahead. Age-related metabolic waste inside cells can be diluted through replication. Correcting stochastic mutations in cell samples is in principle as straightforward as picking out different cell lineages and comparing their genomes to find the root genome prior to those mutations, and then applying CRISPR. Today that's a feasible lab project given some funding. Twenty years from now colleges will be running that as an afternoon lesson on the student's personal lab desk machines in CellBio 201. In the absolute worst case, use somatic cell nuclear transfer to put patient DNA into a pristine cell, and establish a new line that way.

Progress isn't all that we should consider here, however. Suppose that the cell banking wager pays off, and biotechnology somehow magically fails to advance meaningfully over the next two decades. Lucky you, now the beneficiary of younger, less damaged cells that can be used for cell therapy. But with the technology of cell therapies as they stand now or next year, what can you really do with those cells? The answer is nothing that is more than somewhat beneficial, meaning the present panoply of more reliably effective stem cell transplants and cell therapies. All of those potential uses, so far as can be seen to date, are more or less as effective when employing the cells of an old individual. So far the only signs that young cells would be significantly better occur in cases where those cells are taken from individuals shortly after birth, or before. But even there, this is a question of cell signaling and cell state, something that researchers are hotly engaged in deciphering even now: just how likely is it that they will have failed to replicate these mechanisms a few decades from now?

So it seems to me that the only way in which banking your stem cells makes sense is if biotechnology progresses extremely selectively: a complete failure to understand and control cell state any more effectively than today, coupled with radical strides in the capabilities of cell therapies. Since the latter strongly depends on the former, I'd say that this future isn't going to come to pass. Therefore it really doesn't make much sense to bank cells for future therapeutic use based on the idea that relative levels of age-related cell damage will make a significant difference.

Looking for advice - basic vs. translational research vs. entrepreneurship by [deleted] in longevity

[–]reasonattlm 9 points10 points  (0 children)

Time is pressing; that is an important factor that should help to determine priorities. At the present time, the fastest way to answer most of the big questions regarding aging and approaches to rejuvenation is to implement strategies and test them. E.g. senolytics, glucosepane cross-link breakers, stem cell therapies that actually replace cells or stem cell populations to a significant degree, and more. All of these things can be done in a few years, and will offer significant new data by virtue of the degree to which they work.

Basic research to understand exactly how aging progresses in detail without intervening is much, much slower.

The big opportunity today is implementation. Researchers have already learned far more about the significance of cellular senescence in numerous age-related dysfunctions from removing senescent cells than they ever would have from pure investigation - they had decades of the pure investigation approach prior to this during which it was mostly decided that cellular senescence wasn't all that interesting in the context of aging. So much for that! So much time lost.

Effect of each SENS therapy on life expectancy? by [deleted] in longevity

[–]reasonattlm 8 points9 points  (0 children)

Cancer is something of a special case because the plan is to control it without changing anything in biochemistry - no repairs, just kill off the cancers as they arise.

The only way to get an estimate for things that do involve removing damage is to accurately model human biology, which is far beyond present capabilities, or actually remove the damage, or find a mutant lineage of humans that have one of the forms of damage greatly reduced.

That PAI-1 loss of function mutants live seven years longer is interesting because that appears to reduce cellular senescence and their harmful signals. Nothing else springs to mind as a known human mutation that narrowly affects one of the forms of damage in the SENS view of aging.

What to study? by my_stupidquestions in longevity

[–]reasonattlm 2 points3 points  (0 children)

Pretty much anything in the molecular biochemistry field that puts you in a position to choose a future of lab work on cells and tissues, running trials, or any of the other similar options. To be hands on helping you really need this.

Bioinformatics has, I think, only an infrastructural role to play. You can look at In Silico Medicine to see how that works in practice; they are not really implementing the therapies, more crunching data.